Royalty Pharma (RPRX) Q4 2025 earnings summary

Executive summary

• Achieved double-digit growth in 2025, with Portfolio Receipts up 16% to $3,254M and Royalty Receipts up 13%, surpassing guidance and driven by strong capital deployment and portfolio performance.

• Announced $4.7 billion in royalty transactions and deployed $2.6 billion in capital, marking a record year for synthetic royalty deals.

• Internalized external manager, resulting in significant cost reductions, improved governance, and elimination of management fees.

• Returned $1.7 billion to shareholders through $1.2 billion in share repurchases and over $500 million in dividends; increased dividend by 7% in Q1 2026.

• Positive clinical and regulatory updates for key therapies, including FDA approvals and Phase 3 results for Myqorzo, Tremfya, TEV-'749, deucrictibant, and Trodelvy.

Financial highlights

• FY 2025 Royalty Receipts were $3,127M (+13% YoY), Portfolio Receipts $3,254M (+16% YoY); Q4 Royalty Receipts $856M (+17% YoY), Portfolio Receipts $874M (+18% YoY).

• Adjusted EBITDA for FY 2025 was $2,966M (91.1% of Portfolio Receipts); Portfolio Cash Flow $2,724M (83.7% of Portfolio Receipts).

• Return on Invested Capital was 15.8% and Return on Invested Equity 22.8% for 2025.

• Weighted average share count declined by 5–6% year-over-year due to buybacks.

• Ended 2025 with $619M in cash and $9.2B in investment-grade debt; leverage at 3.0x total debt to Adjusted EBITDA.

Outlook and guidance

• 2026 guidance: Portfolio Receipts of $3,275M–$3,425M, Royalty Receipts growth of 3%–8%.

• Operating and professional costs expected to drop to 5.5%–6.5% of Portfolio Receipts in 2026.

• Interest paid projected at $350M–$360M in 2026, up due to new notes issued.

• Guidance reflects loss of exclusivity for Promacta, biosimilar Tysabri launch, and IRA impact.

• Milestones and other contractual receipts expected to decrease from $128M in 2025 to $60M in 2026.